Kairos Pharma Ltd Sustainability Reports
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics to reverse drug resistance and immune suppression in cancer patients. Its portfolio includes antibodies and small molecules targeting various cancer types, such as prostate and lung cancer.
Sector: Manufacturing
Country: United States
Exchange: NYSE American
FIGI: BBG01JLR1S38
1 reports from 2024 to 2024
Company Profile
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics to reverse drug resistance and immune suppression in cancer patients. Its portfolio includes antibodies and small molecules targeting various cancer types, such as prostate and lung cancer.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
